Federal healthcare programs are often well-intended but end up costing more than expected and become subject to waste, fraud, abuse, and mismanagement. One of the best (or worst) examples of such a result is the 340B Drug Pricing Program, which is administered by the Health Resources and Services Administration (HRSA). The lack of clear intent […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
President Trump has made government efficiency a top priority. These efforts include eliminating improper payments and ensuring that only those who are eligible for government programs receive the benefits, including Medicaid. As President Trump said on “Meet the Press” on Sunday, May 4, 2025, “if illegal immigrants are in the mix, if people that aren’t […]
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
On January 5, 2024, the U.S. FDA authorized Florida’s drug importation program.
The use of march-in rights to steal intellectual property will neither lower costs nor create more access to healthcare.
IRA drug price controls will devastate future drug development, resulting in more lives lost.
House Democrats’ new bill on price controls will devastate future drug development and raise costs.
Pharmaceutical price controls in President Biden’s budget and the SMART Choices Act will devastate drug development.
